# A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

> **NCT04227847** · PHASE1 · RECRUITING · sponsor: **Seagen, a wholly owned subsidiary of Pfizer** · enrollment: 178 (estimated)

## Conditions studied

- Myelodysplastic Syndrome
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** SEA-CD70
- **DRUG:** azacitidine
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT04227847
- **Lead sponsor:** Seagen, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-08-07
- **Primary completion:** 2027-07-04
- **Final completion:** 2028-07-03
- **Target enrollment:** 178 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04227847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04227847, "A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04227847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*